CAMP4 Therapeutics Corporation Paid-in-Kind Interest
CAMP4 Therapeutics Corporation (CAMP) reported Paid-in-Kind Interest of $2.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:PaidInKindInterest · last filed 2026-08-13
- CAMP4 Therapeutics Corporation paid-in-kind interest for the quarter ending 2026-06-30 was $1.00K.
- CAMP4 Therapeutics Corporation paid-in-kind interest for the quarter ending 2026-03-31 was $1.00K, a 99.10% decline year-over-year.
- CAMP4 Therapeutics Corporation paid-in-kind interest for the quarter ending 2025-12-31 was -$1.00K, a 106.67% decline year-over-year.
- CAMP4 Therapeutics Corporation paid-in-kind interest for the quarter ending 2025-09-30 was $1.00K, a 94.74% decline year-over-year.
- CAMP4 Therapeutics Corporation paid-in-kind interest for fiscal 2025 was $16.00K, a 80.72% decline from fiscal 2024.
- CAMP4 Therapeutics Corporation paid-in-kind interest for fiscal 2024 was $83.00K, a 9.78% decline from fiscal 2023.
- CAMP4 Therapeutics Corporation paid-in-kind interest for fiscal 2023 was $92.00K.
| Period end | Paid-in-Kind Interest 3 month | Paid-in-Kind Interest 6 month | Paid-in-Kind Interest 9 month | Paid-in-Kind Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $2.00K 10-Q · filed 2026-08-13 | $1.00K derived: sum of 3 quarters · filed 2026-08-13 | $2.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $1.00K 10-Q · filed 2026-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-05-07 | $1.00K derived: sum of 3 quarters · filed 2026-05-07 | -$94.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $0.00 derived: sum of 2 quarters · filed 2026-03-05 | -$95.00K derived: sum of 3 quarters · filed 2026-08-13 | $16.00K 10-K · filed 2026-03-05 |
| 2025-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$94.00K derived: sum of 2 quarters · filed 2026-08-13 | $17.00K 10-Q · filed 2025-11-06 | $32.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$95.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $16.00K 10-Q · filed 2026-08-13 | $31.00K derived: sum of 3 quarters · filed 2026-08-13 | $50.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $111.00K 10-Q · filed 2026-05-07 | $126.00K derived: sum of 2 quarters · filed 2026-05-07 | $145.00K derived: sum of 3 quarters · filed 2026-05-07 | $167.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $15.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $34.00K derived: sum of 2 quarters · filed 2026-03-05 | $56.00K derived: sum of 3 quarters · filed 2026-03-05 | $83.00K 10-K · filed 2026-03-05 |
| 2024-09-30 | $19.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $41.00K derived: sum of 2 quarters · filed 2025-11-06 | $68.00K 10-Q · filed 2025-11-06 | $98.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $22.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $49.00K 10-Q · filed 2025-08-14 | $79.00K derived: sum of 3 quarters · filed 2025-08-14 | |
| 2024-03-31 | $27.00K 10-Q · filed 2025-05-13 | $57.00K derived: sum of 2 quarters · filed 2025-05-13 | ||
| 2023-12-31 | $30.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $92.00K 10-K · filed 2025-03-27 | ||
| 2023-09-30 | $62.00K 10-Q · filed 2024-11-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |